OWC Pharmaceutical Research Corp Raises $5 Million in Preferred Stock Sale to Institutional Investor

Thursday, May 3, 2018 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

RAMAT GAN, Israel, May 3, 2018 /PRNewswire/ --

OWC Pharmaceutical Research Corp. (OWCP),

a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the closing of the sale of $5 million of convertible preferred stock to an institutional investor.
The preferred stock is convertible into OWCP common stock at a price of $0.20 per share. Newbridge Securities Corporation, through LifeTech Capital, acted as exclusive placement agent for the transaction.

     (Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )

The company also issued warrants to purchase 12.5 million shares of common stock to the investor.

The preferred stock, designated as Series A Preferred Stock, accrues dividends, payable quarterly, at a rate of 5% per annum on the amount invested, payable, in the company's discretion subject to customary restrictions, in cash or common stock. The preferred stock has a liquidation preference of 120% of the amount invested. The company has certain obligations to redeem preferred stock upon the occurrence of certain events, and as to half of the shares over time, and the right to force a conversion of the preferred stock under certain conditions.

"This financing is an important milestone for the company," said Mordechai Bignitz, CEO of OWC Pharmaceutical Research. "It enables us to continue to invest in the research and development of our products and to progress our clinical development, which is key to the uniqueness of our company. With this financing, we can also consolidate our movement to commercialization of our first products. We are also very happy to strengthen the institutional presence amongst our shareholders."

About OWC Pharmaceutical Research Corp.  OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company') conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.

OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.

Mordechai Bignitz, Chief Executive Officer - OWC Pharmaceutical research crop, Email: Mordechai.Bignitz@owcpharma.com Tel: +972-(72)-260-8004

SOURCE OWC Pharmaceutical Research Corp.

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store